Some of the world’s top scientific leaders in the field will highlight the current progress of artificial intelligence...
A nanoparticle-based flu vaccine discovered and developed by the Vaccine Research Center, National Institute of Allergy...
An initiative at Frederick National Laboratory for Cancer Research (FNL) is confronting what’s been dubbed the...

All News

[Apply]
Category
Date Posted Range

BIO International Convention 2022: Pursuing the mission of the Frederick National Laboratory in San Diego

Partnership Development OfficePosted 8/4/2022
Pursuing future partners and better weather, the Frederick National Laboratory for Cancer Research (FNL) recently attended the BIO 2022 International Convention in San Diego. This convention is one of the largest biotech partnering events internationally, with over 3,000 foreign and domestic companies represented at this year’s week-long June event. This setting created an…

Five new innovative projects awarded LDER funding

Laboratory-Directed Exploratory Research, Cancer Data Science Initiatives, AIDS and Cancer Virus Program, Basic Science ProgramPosted 7/21/2022
Five new projects led by Frederick National Laboratory for Cancer Research (FNL) scientists have earned Laboratory Directed Exploratory Research (LDER) funding for the upcoming fiscal year. The LDER program, which was modeled after the U.S. Department of Energy’s Laboratory Directed Research and Development program, provides FNL scientists the opportunity to compete for…

Hood College symposium to explore artificial intelligence in cancer research and clinical care

Cancer Data Science Initiatives, Partnership Development OfficePosted 7/7/2022
Some of the world’s top scientific leaders in the field will highlight the current progress of artificial intelligence (AI) applications in cancer research and clinical care at a scientific symposium hosted by Hood College in partnership with the Frederick National Laboratory for Cancer Research, September 20-22. Cancer researchers are invited to attend the conference…

COVID-19 vaccines bring nanomedicine back into the spotlight

Nanotechnology Characterization LaboratoryPosted 6/15/2022
The success of today’s COVID-19 vaccines has given medical nanotechnology a long-awaited boost, with a renewed interest in its potential for treating disease among big pharma and small start-ups. Over the years, nanotechnology has had its ups and downs in the public eye, cycling from peaks of excitement and fanfare–and a little too much hype–to falling out of favor because…

Nanotechnology experts share insights as they see similarities in hypersensitivity reactions to nanomedicine and mRNA vaccines

Nanotechnology Characterization LaboratoryPosted 5/18/2022
When nanoparticle-based mRNA COVID-19 vaccines were made available in December 2020 and the media began to report the incidence of rare but troubling anaphylaxis, nanomedicine experts including Frederick National Laboratory’s Marina Dobrovolskaia recognized those hypersensitivity reactions. “Everything they reported symptomatically sounded so familiar to us from our work…

Computing collaboration makes massive microscopy analyses possible

Posted 5/11/2022
On any given day, microscopist Susan Lea, D.Phil., and her team at NCI at Frederick collect more data than can fit on any standard hard drive, creating a challenge for data storage and analysis. Their average data collection is 5 terabytes, a quantity roughly 20 times the storage capacity of a 256-gigabyte laptop or the equivalent of storing about 1,250 movies. The…

Nanoparticle-based flu vaccine performs well in early phase clinical trial

Vaccine Clinical Materials ProgramPosted 5/5/2022
A nanoparticle-based flu vaccine discovered and developed by the Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), was manufactured by Frederick National Laboratory (FNL) for a Vaccine Research Center Phase 1 clinical trial. The vaccine was found to be safe, well-tolerated, and immunogenic against multiple flu subtypes and, with further…

Scientists to present multidisciplinary studies at AACR Annual Meeting

Partnership Development Office, Molecular Characterization Laboratory, Meet us at AACRPosted 4/6/2022
Investigators from the Frederick National Laboratory for Cancer Research will share their latest work regarding the use of pre-clinical models for compound screening and tumor characterization, bioinformatics and technology initiatives, among other topics, at the American Association for Cancer Research 2022 Annual Meeting. More than 30 abstracts by Frederick…

STAR TREC takes on reproducibility, standardization, and better science

STAR TREC, Partnership Development Office, Leonard Freedman, Ph.D.Posted 4/4/2022
An initiative at Frederick National Laboratory for Cancer Research (FNL) is confronting what’s been dubbed the scientific “reproducibility crisis.” The effort, called STAR TREC (the Standards References and Training Research Committee), seeks to help the scientific community address reproducibility issues and aims to spur dialogue about better standards in science.…

New study finds classical RAS proteins are not essential for RAF inhibitor-induced paradoxical ERK activation

RAS InitiativePosted 4/1/2022
The classical RAS family of proteins functions as molecular switches at the cell’s plasma membrane where it cycles between an active and inactive state. The active state initiates a cascade of events that promote downstream signaling to regulate cellular functions, such as cell proliferation. Mutations and dysregulation of the RAS-RAF-MEK-ERK signaling pathway are among…